Zonisamide and renal calculi in patients with epilepsy: How big an issue?

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1765-1773

  Wroe, Stephen ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Antiepileptic drug; Pooled analysis; Urolithiasis; Zonisamide

Indexed keywords

OXCARBAZEPINE; PLACEBO; TOPIRAMATE; ZONISAMIDE;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER OBSTRUCTION; BLADDER STONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG MARKETING; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EPILEPSY; FEMALE; HEMATURIA; HUMAN; HYDRONEPHROSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCREENING; SIDE EFFECT; URINARY TRACT INFECTION; URINE; UROLITHIASIS;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; ISOXAZOLES; KIDNEY CALCULI; MALE; MIDDLE AGED; PLACEBOS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34548133086     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210499     Document Type: Article

References (38)

1. Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int 2004;72(Suppl 1):1-5
2. Wasserstein AG. Nephrolithiasis: acute management and prevention. Dis Mon 1998;44:196-213
3. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol 2000;13(Suppl 3):S45-S50
4. Pak CYC. Kidney stones. Lancet 1998;351:1797-801
5. Stametalou KK, Frances ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23
6. Abdel Goad EH, Bereczky ZB. Metabolic risk factors in patients with renal stones in KwaZulu Natal: an inter-racial study (Asian and Whites). BJU Int 2004;93:120-3
7. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005;115:2598-608
8. Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004;64:245-75
9. Jaeger P. Genetic versus environmental factors in renal stone disease. Curr Opin Nephrol Hypertens 1996;5:342-6
10. Khan AS, Rai ME, Gandapur et al. Epidemiological risk factors and composition of urinary stones in Riyadh Saudi Arabia. J Ayub Med Coll Abbottabad 2004;16:56-8
11. Maloney ME, Springhart WP, Ekeruo WO, et al. Ethnic background has minimal impact on the etiology of nephrolithiasis. J Urol 2005;173:2001-4
12. Moe OW. Kidney stones: pathophysiology and medical management. Lancet 2006;367:333-44
13. Parmar MS. Kidney stones. BMJ 2004;328:1420-4
14. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-62
15. Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996;30:514-9
16. Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of myoclonic epilepsy. Neurology 1990;40:1677-81
17. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology 1981;88:261-5
18. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41 (Suppl 1):S66-S71
19. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35-S39
20. de Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315-20
21. Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004;41:166-9
22. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13(Suppl 1):S59-S65
23. Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68(Suppl. 2):S3-S9
24. Macdonald RL. Zonisamide. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 867-72
25. Masuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects. Arzneim-Forsch 1994;44:267-9
26. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneim-Forsch 1993;43:416-7
27. Faught E, Ayala R, Montouris G, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9
28. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:1-11
29. Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-7
30. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73
31. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73
32. Kubota M, Nishi-Nagase M, Sakakihara Y, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000;22:230-3
33. Hasegawa H. Zonisamide adjunct therapy for elderly intractable seizure in VA outpatient clinic. Epilepsia 2003;44(Suppl 9):17 [abstract 1.038]
34. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(Suppl 2):S18-S22
35. Jonas R, Desai SS, Wu JY, et al. Topiramate, zonisamide, and the ketogenic diet: incidence of nephrolithiasis. Epilepsia 2002;43(Suppl 7):59 [abstract 1.161]
36. Vazquez B, Ghacibeh G, Hopkins M, Devinsky O. Zonisamide and topiramate combination therapy: safety and tolerability. Epilepsia 2001;42(Suppl 7):261 [abstract 3.137]
37. Rosenfeld WE. Safety and tolerability of zonisamide used concurrently with topiramate. Epilepsia 2001;42(Suppl. 7):260 [abstract 3.131]
38. Richards KC, Smith MC, Verma A. Continued use of zonisamide following development of renal calculi. Neurology 2005;64:763-4